



Otsuka Pharmaceutical Development  
& Commercialisation Europe GmbH

Europa-Allee 52  
60327 Frankfurt am Main  
Germany  
Tel.: +49 69 955 044 0

Date: 02 May 2023

Dr. Harald Enzmann  
European Medicines Agency  
Domenico Scarlattilaan 6  
1083 HS Amsterdam  
The Netherlands

**Subject: Withdrawal of Asimtufii (aripiprazole) 720 mg and  
960 mg prolonged-release suspension for injection in pre-filled  
syringe - EMEA/H/C/005929**

Dear Dr. Harald Enzmann,


We would like to inform you that, at this point of time, Otsuka Pharmaceutical Netherlands B.V., has taken the decision to withdraw the application for Marketing Authorisation of Asimtufii (aripiprazole) 720 mg and 960 mg prolonged-release suspension for injection in pre-filled syringe, which was intended to be used for the maintenance treatment of schizophrenia in adult patients stabilised with aripiprazole.

This withdrawal is based on the following reason: a change in Otsuka's strategy. This is unrelated to product quality or safety.


We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

We agree for this letter to be published on the EMEA website.

Yours sincerely,



Associate Director, Global Regulatory Affairs Region Europe  
Otsuka Pharmaceutical Development & Commercialisation  
Europe GmbH



Managing Director  
Otsuka Pharmaceutical Netherlands B.V.